CD25-biased anti-IL-2 antibody
AssigneeUniversitäT ZüRich
InventorsOnur Boyman, Ufuk Karakus, Miro Raeber, Roman Meledin, Robert Maka
Life of this patent
Estimating the term…
Abstract
The invention provides a human IL-2 (hIL-2)-specific monoclonal antibody, wherein a complex of hIL-2 and the monoclonal induces IL-2 signalling preferentially via CD25 and the trimeric IL-2R. The invention further provides a pharmaceutical composition comprising hIL-2 and said hIL-2-mAb for use treating inflammatory disease.
Claims11
A human interleukin-2 (hIL-2)-specific monoclonal antibody (mAb), or antigen-binding fragment thereof, wherein the hIL-2-specific mAb interacts with hIL-2 amino acid residues to provide an epitope, and
- wherein the epitope comprises the hIL-2 residues
- H16, D20,
- Q57, E60, E61, L63, K64, E67, E68, and
- L80, R81, R83, D84, 186, S87, N88, N90, V91, L94, E95, K97, T101, T102, M104;
- wherein the hIL-2-specific mAb, or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising a VH complementarity determining region CDRH1, CDRH2 and CDRH3, and a variable light chain (VL) region comprising a VL complementarity determining region CDRL1, CDRL2 and CDRL3, and wherein
- a. CDRH1 comprises, or is identical to SEQ ID NO 001;
- and
- b. CDRH2 comprises, or is identical to SEQ ID NO 002, and
- c. CDRH3, comprises, or is identical to SEQ ID NO 003;
- and
- d. CDRL1 comprises, or is identical to SEQ ID NO 004;
- and
- e. CDRL2 comprises, or is identical to SEQ ID NO 005;
- and
- f. CDRL3 comprises, or is identical to SEQ ID NO 006.
A hIL-2-specific mAb, or antigen-binding fragment thereof, which comprises a heavy chain variable (VH) region comprising a VH complementarity determining region CDRH1, CDRH2 and CDRH3, and a variable light chain (VL) region comprising a VL complementarity determining region CDRL1, CDRL2 and CDRL3, and wherein
- a. CDRH1 comprises, or is identical to SEQ ID NO 001;
- and
- b. CDRH2 comprises, or is identical to SEQ ID NO 002, and
- c. CDRH3, comprises, or is identical to SEQ ID NO 003;
- and
- d. CDRL1 comprises, or is identical to SEQ ID NO 004;
- and
- e. CDRL2 comprises, or is identical to SEQ ID NO 005;
- and
- f. CDRL3 comprises, or is identical to SEQ ID NO 006.
Dependencies are inferred from the claim text.